Specialized Medical Company (4019.SR)
40 additional metrics available with a Kvantra account
No price history available.
Key financial summary
Financials in SAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SARm | N/A | 1,052 | 1,207 | 1,366 | 1,437 | 1,538 | 1,572 | 1,663 |
| Operating profit | SARm | ||||||||
| Net profit | SARm | N/A | 56 | 103 | 168 | 185 | 266 | 278 | 240 |
| EPS reported | SAR | ||||||||
| Operating cashflow per share | SAR | ||||||||
| Capex per share | SAR | ||||||||
| FCF per share | SAR | ||||||||
| Free cash flow | SARm | ||||||||
| Net debt | SARm | ||||||||
| Book value equity | SARm | ||||||||
| Book value per share | SAR | ||||||||
| Number of shares | m | ||||||||
| DPS (TTM paid) | SAR |
Financial summary
Financials in SAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | ||||||||
| P/B LTM | x | ||||||||
| P/S LTM | x | ||||||||
| P/FCF LTM | x | ||||||||
| EV/EBITDA LTM | x | ||||||||
| EV/Sales LTM | x | ||||||||
| Earnings Yield LTM | % | ||||||||
| FCF Yield | % | ||||||||
| Quality | |||||||||
| ROE | % | ||||||||
| ROIC | % | ||||||||
| Operating margin | % | ||||||||
| Gross margin | % | ||||||||
| FCF/Sales | % | ||||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | ||||||||
| Sales Growth YoY | % | ||||||||
| Net Income Growth YoY | % | ||||||||
| FCF Growth | % | ||||||||
| Operating Profit Growth | % | ||||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | ||||||||
| Dividend Growth | % | ||||||||
| Payout Ratio | % | ||||||||
| FCF/Debt | x | ||||||||
| Net Debt/EBITDA | x | ||||||||
| EBIT/Net interest | x | ||||||||
| Net debt/market cap | % | ||||||||
| Net debt/Equity | % | ||||||||
| Gross debt/equity | % | ||||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Based in Riyadh, Saudi Arabia, and established in 1994, Specialized Medical Company operates an extensive network of hospitals, clinics, and medical centers throughout the Kingdom. Its diverse activities are categorized into two primary segments: Medical Services, and Pharmacies & Other Offerings. The company delivers a full spectrum of medical care, encompassing both diagnostic and therapeutic treatments across numerous specialties. These include urgent care, cardiology, internal and family medicine, and pediatrics. Essential ancillary services are also provided, such as laboratory diagnostics (including histopathology), advanced imaging (radiology and nuclear medicine), anesthesiology, pharmaceutical supply, and physiotherapy rehabilitation. Furthermore, Specialized Medical Company boasts comprehensive surgical capabilities, with specialized units for operating rooms, post-operative recovery, maternity (delivery), ophthalmology, general surgery, obstetrics and gynecology, urology, orthopedics, and ear, nose, and throat (ENT) procedures. Critical care is a key offering, featuring specialized intensive care units for neonates (NICU), cardiac patients (CCU), and general critical conditions (ICU). Beyond conventional medicine, the company extends its portfolio to include dermatology, anti-aging, aesthetic services, home healthcare, virtual consultations, and dentistry. In addition to its healthcare provisions, the company's "Pharmacies & Other" segment encompasses a range of services such as the provision of prepared and unprepared food, maintenance for hospital and other facilities, and the management and operation of restaurants, alongside other non-medical, healthy food, and food-related enterprises.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Specialized Medical Company (4019.SR)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Based in Riyadh, Saudi Arabia, and established in 1994, Specialized Medical Company operates an extensive network of hospitals, clinics, and medical centers throughout the Kingdom. Its diverse activities are categorized into two primary segments: Medical Services, and Pharmacies & Other Offerings. The company delivers a full spectrum of medical care, encompassing both diagnostic and therapeutic treatments across numerous specialties. These include urgent care, cardiology, internal and family medicine, and pediatrics. Essential ancillary services are also provided, such as laboratory diagnostics (including histopathology), advanced imaging (radiology and nuclear medicine), anesthesiology, pharmaceutical supply, and physiotherapy rehabilitation. Furthermore, Specialized Medical Company boasts comprehensive surgical capabilities, with specialized units for operating rooms, post-operative recovery, maternity (delivery), ophthalmology, general surgery, obstetrics and gynecology, urology, orthopedics, and ear, nose, and throat (ENT) procedures. Critical care is a key offering, featuring specialized intensive care units for neonates (NICU), cardiac patients (CCU), and general critical conditions (ICU). Beyond conventional medicine, the company extends its portfolio to include dermatology, anti-aging, aesthetic services, home healthcare, virtual consultations, and dentistry. In addition to its healthcare provisions, the company's "Pharmacies & Other" segment encompasses a range of services such as the provision of prepared and unprepared food, maintenance for hospital and other facilities, and the management and operation of restaurants, alongside other non-medical, healthy food, and food-related enterprises.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free